“Long-Term Durability and Stability of Amlitelimab Efficacy in Adults With Moderate-to-Severe Atopic Dermatitis: 52-Week Post Hoc Analysis of the STREAM-AD Phase 2b Trial”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 6, Nov. 2025, p. s607, https://doi.org/10.25251/qx64pd52.